Weekly Cosmetic Research Analysis
This week showed high-impact, practice-changing work across cosmetic surgery, cosmeceuticals, and regenerative therapeutics. A blinded randomized split‑scar RCT favored rapidly absorbable polyglactin 910 for superior 6‑month facial scar cosmesis, providing immediately actionable guidance for epidermal closure. Mechanistic cosmeceutical work identified an Nrf2/ARE–AKR1C–PGF2α axis mediating kukui nut oil–driven hair/eyelash growth with randomized human eyelash data, bridging discovery to product
Summary
This week showed high-impact, practice-changing work across cosmetic surgery, cosmeceuticals, and regenerative therapeutics. A blinded randomized split‑scar RCT favored rapidly absorbable polyglactin 910 for superior 6‑month facial scar cosmesis, providing immediately actionable guidance for epidermal closure. Mechanistic cosmeceutical work identified an Nrf2/ARE–AKR1C–PGF2α axis mediating kukui nut oil–driven hair/eyelash growth with randomized human eyelash data, bridging discovery to product development. Preclinical nanozyme–EV therapeutics demonstrated a coherent DNA‑repair platform that reverses senescence in intervertebral disc degeneration, signaling broader implications for anti‑aging regenerative approaches.
Selected Articles
1. Photographic Assessment of Cosmetic Outcome in Postsurgical Facial Scars Favors Rapidly Absorbable Polyglactin 910 Over Fast Absorbing Gut: A Blinded Randomized Clinical Trial.
A blinded randomized split-scar RCT (n=105) comparing 5-0 Vicryl Rapide (polyglactin 910) versus 5-0 fast absorbing gut for epidermal closure after Mohs surgery found superior dermatologist-rated photographic cosmesis at 6 months (significant differences in VAS, SBSES, WES). The study used within-patient controls and standardized photo assessment to reduce confounding.
Impact: Provides high-quality, directly actionable randomized evidence to inform suture choice for facial epidermal closure, with immediate implications for aesthetic outcomes in cutaneous surgery.
Clinical Implications: Clinicians performing facial epidermal closure should consider prioritizing rapidly absorbable polyglactin 910 (Vicryl Rapide) to improve 6-month cosmetic outcomes; counsel patients about expected benefits and monitor longer-term durability.
Key Findings
- Blinded split-scar RCT (n=105) comparing 5-0 Vicryl Rapide vs 5-0 fast absorbing gut.
- Dermatologist photographic ratings favored polyglactin 910: VAS 76.5 vs 73.2 (p=.05); SBSES 4.4 vs 4.0 (p=.006); WES 5.4 vs 5.1 (p=.05) at 6 months.
- Plastic surgeon ratings trended in the same direction but were not statistically significant.
2. Kukui nut oil (Aleurites moluccanus seed oil) promotes hair growth by activating the Nrf2/ARE-AKR1C family-PGF2α signaling axis.
Ex vivo human hair follicle assays and transcriptomics linked kukui nut (A. moluccanus seed) oil to activation of Nrf2/ARE, upregulation of AKR1C enzymes, increased PGF2α, and proliferation markers; a randomized double-blind left-right human test confirmed enhanced eyelash growth, connecting mechanism to clinical effect.
Impact: Mechanistically defines an Nrf2/ARE–AKR1C–PGF2α axis for a widely used cosmetic ingredient and provides randomized human evidence for eyelash efficacy—bridging bench mechanistic discovery with translational cosmeceutical potential.
Clinical Implications: Supports development of topical formulations targeting the Nrf2/AKR1C–PGF2α pathway for hair and eyelash growth; recommends further dose–response, safety, and comparative studies against existing prostaglandin analogs before broad clinical adoption.
Key Findings
- AMS oil promoted hair growth in ex vivo human hair follicle culture.
- Increased PGF2α and upregulation of AKR1C family enzymes were observed alongside proliferation marker increases.
- Transcriptomics linked effects to Nrf2/ARE activation; randomized double-blind left-right human test confirmed eyelash growth.
3. A continuous DNA repairing system for alleviating intervertebral disc degeneration.
A preclinical platform combining bimetallic-curcumin nanozymes (AuCu-Cur) with human umbilical cord‑derived EVs scavenged ROS, upregulated NEIL3-mediated DNA repair, promoted DNA replication and ECM synthesis, and markedly attenuated intervertebral disc degeneration in a rat puncture model; clinical translation requires large-animal safety and biodistribution studies.
Impact: Presents a mechanistically coherent, multi-modal therapeutic approach that targets DNA damage–driven senescence with in vivo efficacy—potentially paradigm-shifting for degenerative and anti‑aging strategies.
Clinical Implications: Though preclinical, the platform supports further translational work toward nanozyme–EV therapeutics for degenerative conditions; recommends biomarker development (SASP/NEIL3) and GMP-grade production and safety testing prior to human trials.
Key Findings
- Single-cell sequencing linked oxidative stress to DNA damage and SASP in IVDD.
- AuCu-curcumin nanozymes scavenged ROS and enhanced NEIL3-associated DNA repair in nucleus pulposus cells.
- hUCMSC-EVs improved nanozyme bioavailability, promoted DNA replication via p-JNK, and the combined system ameliorated disc degeneration in a rat model.